Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.71 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.67 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.62 |
| ▸ | FPGS | Q05932 | 2/20 | 0.60 |
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
| ▸ | GART | P22102 | 5/20 | 0.55 |
| ▸ | ATIC | P31939 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucovorin SCHEMBL159828 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL4575698 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL258832 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL3031362 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Folinic Acid SCHEMBL29616563 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL29385578 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL29379632 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL36113 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Folinic Acid SCHEMBL21498299 | 1.00 | DHFR (1.00) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL4744838 | 0.99 | DHFR (0.98) | DHFRLMNAMTHFD1SOSTMTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 628 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048057-A1 | ANTI-ISCHEMIC COMPOSITIONS | FAGRELL BENGT (SE) | 2026-02-19 | — | — | US | claimed |
| EP-4688828-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF | Jubilant DraxImage Inc. (CA) | 2026-02-11 | — | — | EP | claimed |
| US-12472183-B2 | Anti-ischemic compositions | Fagrell, Bengt (SE) | 2025-11-18 | — | — | US | claimed |
| CN-120142506-A | Kit for determining folic acid and metabolite thereof in erythrocytes by high performance liquid chromatography tandem mass spectrometry | 河北乾业生物科技有限公司 | 2025-06-13 | — | — | CN | claimed |
| WO-2025092703-A1 | PHOTOSENSITIZER CONJUGATE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 同宜医药（苏州）有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-113453720-B | Dual ligand drug conjugate and uses thereof | 同宜医药（苏州）有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-117064062-B | Method for improving folic acid stability and bioavailability and application thereof | 暨南大学 | 2025-02-25 | — | — | CN | claimed |
| US-20240415837-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | MACHOVER DAVID (FR) | 2024-12-19 | — | — | US | claimed |
| CN-119031938-A | Compounds and uses | 同宜医药（苏州）有限公司 | 2024-11-26 | — | — | CN | claimed |
| US-20240358843-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2024-10-31 | — | — | US | claimed |
| US-6121195-A | STIMULATING CARBON FIXATION AND INCREASING THE GROWTH OF PLANTS BY ENHANCING THE AVAILABILITY OF C1-TETRAHYDROFOLATE IN THE LEAVES OF A PLANT | NONOMURA ARTHUR M (US) | 2000-09-19 | — | — | US | claimed |
| EP-0813510-A4 | METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS | NONOMURA ARTHUR M (US) | 2000-07-26 | — | — | EP | claimed |
| US-6008221-A | REDUCING HOMOCYSTEINE IN BLOOD LEVEL ON THE VASCULATURE OR ON NERVE CELLS IN THE BRAIN, DETOXIFICATION, TREATING NEURODEGENERATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-28 | — | — | US | claimed |
| EP-0951293-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0675719-B1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | WELLCOME FOUND (GB) | 1998-06-10 | — | — | EP | claimed |
| WO-1998019690-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-14 | — | — | WO | claimed |
| EP-0813510-A1 | METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS | NONOMURA, Arthur M. (US) | 1997-12-29 | — | — | EP | claimed |
| WO-1996027572-A1 | METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS | NONOMURA ARTHUR M (US) | 1996-09-12 | — | — | WO | claimed |
| EP-0675719-A1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-10-11 | — | — | EP | claimed |
| WO-1994014448-A1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-07-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048057-A1 | ANTI-ISCHEMIC COMPOSITIONS | FABP3, SLC40A1, S100A10 | DHFR 576/4885LMNA 3234/4885MTHFD1 5/4885 |
| US-20240358843-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SELPLG, SELL, SIGLEC7 | DHFR 179/4885LMNA 3552/4885MTHFD1 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.